P021 the Impact of TP53 Mutation and Tumor Mutation Number on Outcomes in Patients With Stage I Non Small Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.045
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.01-44 Prognostic Value of TP53 Hot Exon Mutation in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Integrated Mutation, Copy Number and Expression Profiling in Resectable Non-Small Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2011English

ROS1 Mutation Non-Small Cell Lung Cancer—access to Optimal Treatment and Outcomes

ecancermedicalscience
Cancer ResearchOncology
2019English

EGFR Mutation Status in Tunisian Non-Small-Cell Lung Cancer Patients Evaluated by Mutation-Specific Immunohistochemistry

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2018English

MA06.07 Genetic and Epigenetic Alterations Are Associated With Tumor Mutation Burden in Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Predictive Factors in Patients With EGFR Mutation‑negative Non‑small Cell Lung Cancer Treated With Erlotinib

Oncology Letters
Cancer ResearchOncology
2014English

Non-Invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2015English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancers
Cancer ResearchOncology
2019English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy